Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy

被引:59
|
作者
Gallafent, JH
Buskin, SE
De Turk, PB
Aboulafia, DM
机构
[1] Univ Washington, Sch Med, Virginia Mason Med Ctr, Seattle, WA 98111 USA
[2] Virginia Mason Med Ctr, Div Hematol Oncol, Seattle, WA 98101 USA
[3] Virginia Mason Med Ctr, Dept Epidemiol, Seattle, WA 98101 USA
[4] Virginia Mason Med Ctr, Publ Hlth Seattle & King Cty, HIV AIDS Epidemiol Program, Seattle, WA 98101 USA
关键词
D O I
10.1200/JCO.2005.04.156
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Since the advent of highly active antiretroviral therapy (HAART), the incidence of Kaposi's sarcoma (KS) among AIDS patients has declined both nationwide and in King County, Washington. We sought to compare clinical parameters of patients diagnosed with KS in the pre-HAART (1990 to 1996) and HAART (1997 to 2002) eras. Methods We used patient data abstracted from the Adult/Adolescent Spectrum of HIV-Related Diseases study of Public Health-Seattle and King County. Results Patients diagnosed with KS in the HAART era (n = 40) were significantly more likely (P<.05) than pre-HAART-era KS patients (n = 366) to be diagnosed with alcohol problems (43% v 18%), noninjection drug use (45% v 18%), injection drug use (25% v 10%), psychosis (25% v 13%), and hypertension (13% v 2%). Although median CD4(+) count and HIV-1 viral load at the time of KS diagnosis were not significantly different between the two groups, significantly fewer (P <.01) HAART-era KS patients developed opportunistic illnesses (Ols) during their follow-up. The risk of dying among KS patients diagnosed in the HAART era is significantly lower (P <.01) than for KS patients diagnosed in the pre-HAART era (hazard ratio, 0.24). Conclusion Although HAART-era KS patients in King County were as likely to have a depleted CD4(+) cell count and high HIV-1 viral loads at the time of KS diagnosis as pre-HAART KS patients, they survived longer and fewer of them were diagnosed with other Ols. They also had an increased prevalence of substance abuse and mental illness, contributing to a dynamic and changing KS clinical profile.
引用
下载
收藏
页码:1253 / 1260
页数:8
相关论文
共 50 条
  • [41] Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy
    Aboulafia, DM
    MAYO CLINIC PROCEEDINGS, 1998, 73 (05) : 439 - 443
  • [42] Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma
    Bundow, D
    Aboulafia, DM
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (01): : 81 - 84
  • [43] Kaposi's sarcoma: Good outcome with doxorubicin, bleomycin and vincristine sulphate (ABV) chemotherapy and highly active antiretroviral therapy
    Hesseling, P. B.
    Katayi, E.
    Wharin, P.
    Bardin, R.
    Kouya, F.
    Palmer, D.
    Glenn, M.
    Kruger, M.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2017, 107 (11): : 952 - 953
  • [44] Clinical characteristics of HIV-associated Kaposi's sarcoma in the era of combination antiretroviral therapy
    Meyer, L.
    Stoehr, A.
    Horst, H. -A
    Plettenberg, A.
    Lorenzen, T.
    Schewe, K.
    Sabranski, M.
    Hoffmann, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 175 - 175
  • [45] Nutrition in the era of highly active antiretroviral therapy
    Shevitz, AH
    Knox, TA
    CLINICAL INFECTIOUS DISEASES, 2001, 32 (12) : 1769 - 1775
  • [46] Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin
    Torre-Cisneros, J
    Pozo, F
    Serrano, R
    Vidal, E
    Rivero, A
    Tenorio, A
    AIDS, 2000, 14 (14) : 2215 - 2217
  • [47] Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy
    Franceschi, S.
    Dal Maso, L.
    Rickenbach, M.
    Polesel, J.
    Hirschel, B.
    Cavassini, M.
    Bordoni, A.
    Elzi, L.
    Ess, S.
    Jundt, G.
    Mueller, N.
    Clifford, G. M.
    BRITISH JOURNAL OF CANCER, 2008, 99 (05) : 800 - 804
  • [48] AIDS-associated Kaposi sarcoma in Uganda: response to treatment with highly active antiretroviral therapy and chemotherapy
    HQ Nguyen
    F Okuku
    F Ssewankambo
    AS Magaret
    C Johnston
    A Wald
    A Kambugu
    L Corey
    J Orem
    C Casper
    Infectious Agents and Cancer, 4 (Suppl 2)
  • [49] Kaposi sarcoma incidence in the Swiss HIV cohort study before and after highly active antiretroviral therapy
    S Franceschi
    L Dal Maso
    M Rickenbach
    J Polesel
    GM Clifford
    Infectious Agents and Cancer, 4 (Suppl 2)
  • [50] Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy
    S Franceschi
    L Dal Maso
    M Rickenbach
    J Polesel
    B Hirschel
    M Cavassini
    A Bordoni
    L Elzi
    S Ess
    G Jundt
    N Mueller
    G M Clifford
    British Journal of Cancer, 2008, 99 : 800 - 804